An observational study in ACS - Acute Coronary Syndrome, sponsored by Heart Care Foundation. Recruiting at 57 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Heart Care Foundation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Acute Coronary Syndrome with a site in Italy — 25 open to participants now, 29 under way, 2 of them phase 3. Acute Coronary Syndrome · Italy.
Among the 138 studies in Acute Coronary Syndrome with a site in Italy, this one is the 8th largest by planned enrollment of the 52 observational ones that give a count, is one of 8 that started in 2024, is one of 53 observational ones, reaches primary completion later than 20 of the 28 other live ones, and was the 131st registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →25 of the 138 studies in Acute Coronary Syndrome with a site in Italy are open now. Recruiting first, the newest first:
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 30–70
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy
Abcentra · Sites in Italy, United States, Czechia and 6 more countries
Ages 18+
IRCCS San Raffaele · Sites in Italy
Ages 18–100 · Women only
IRCCS San Raffaele · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Median enrollment 522 across the 85 interventional studies, 1,000 across the 52 observational. Of the 76 that completed or were terminated, 20 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 138 have an industry lead sponsor. The 10 most frequent:
Heart Care Foundation is the lead sponsor of 22 studies on the registry; 6 are open to participants now.
Heart Care Foundation has 6 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
9 of the studies in Acute Coronary Syndrome with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07440381Phase 3Heart Care FoundationtriPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE | 2027-08 |
| NCT07588295Maria Cecilia HospitalLocal And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease | 2026-12 |
| NCT01218776University of BolognaInternational Survey of Acute Coronary Syndromes | 2026-12-31 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
| NCT07429227Casa di Cura Dott. PederzoliEvaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status. | 2027-03 |
Add all 9 to your calendar (.ics) → With an account.
Among the 138 studies in Acute Coronary Syndrome with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Major advances in cardiovascular medicine have been driven by innovations in basic research in biological and technical sciences. Despite the clear evidence regarding the treatments that have been demonstrated to be useful to improve patients' outcomes, their transferability to everyday clinical practice seems to be at least suboptimal. The European Society of Cardiology (ESC), therefore, planned to support a program, denominated EuroHeart, for continuous data collection of standardized and/or harmonized variables in common cardiovascular diseases, such as ACS, HF and A Fib. EuroHeart is an observational, prospective, multicentre initiative with continuous data collection in consecutive patients with ACS, HF and A Fib to support continuous quality of care improvement through the evaluation of quality indicators (QIs) defined by the ESC. All patients included in the EuroHeart initiative, will enter a 12 month longitudinal follow-up with the collection of clinical events and clinical status data.
patients with ACS
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EuroHeart is an initiative of the European Society of Cardiology (ESC) supporting continuous quality-of-care improvement through individual patient data collection. The present registry component refers specifically to the Italian implementation of the EuroHeart programme, aimed at monitoring and improving adherence to ESC quality indicators within Italian clinical practice.
Adherence to ESC Quality indicators (STEMI patients reperfused)
Proportion of patients with STEMI reperfused among those eligible (onset of symptoms to diagnosis \<12 hours)
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (STEMI patients reperfused <90 min)
Proportion of patients with STEMI who receive timely reperfusion with PCI (wire crossing) within 90 minutes from initial diagnostic ECG
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (coronary angiography in NSTEMI patients within 24 hours)
Rate of NSTEMI patients who receive invasive within 24 hours from their diagnosis
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (radial access)
Use of radial access in case of invasive strategy for patients with STEMI and NSTEMI
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (time to reperfusion in STEMI patients)
The time between the initial STEMI diagnosis and arterial access (absolute value) for primary PCI
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (pre-discharge LVEF evaluation in STEMI and NSTEMI patients)
The proportion of patients with STEMI and NSTEMI who have an assessment of their left ventricular ejection fraction (LVEF) before hospital discharge
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (in hospital LDL-c evaluation in STEMI and NSTEMI patients)
The proportion of patients with STEMI and NSTEMI who have their LDL cholesterol measured during hospitalization
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (DAPT prescription at discharge in STEMI and NSTEMI patients)
Proportion of patients with STEMI and NSTEMI discharged on dual antiplatelet therapy
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (LLA prescription at discharge in STEMI and NSTEMI patients)
Proportion of patients discharged from hospital on Lipid Lowering Agents (LLA)
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (ACEi/ARB/ARNI prescription at discharge in patients with LVEF ≤40%)
Proportion of patients with LVEF ≤40% who are discharged from hospital on angiotensin converting enzymes inhibitors (ACEi) or angiotensin receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitor (ARNI)
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (Beta blockers prescription at discharge in patients with LVEF ≤40%)
Proportion of patients with LVEF ≤40% who are discharged from hospital on beta blockers.
Time frame: From enrollment to 12 months follow-up
Cardiovascular and non-cardiovascular events during follow-up
Proportion of patients with clinical events at 12 months
Time frame: 12 months follow-up
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.
Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 36 months is close to that.
Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heart Care Foundation